Arrowhead Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1989-01-01
- Employees
- 525
- Market Cap
- $2.9B
- Introduction
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic Patients
- Conditions
- DyslipidemiasFamilial HypercholesterolemiaHypertriglyceridemia
- Interventions
- Drug: sterile normal saline (0.9% NaCl)
- First Posted Date
- 2018-11-20
- Last Posted Date
- 2021-09-21
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 93
- Registration Number
- NCT03747224
- Locations
- 🇦🇺
Linear Clinical Research, Nedlands, Australia
🇳🇿Auckland Clinical Studies Limited, Grafton, Auckland, New Zealand
🇳🇿Middlemore Hospital, Papatoetoe, Aukland, New Zealand
Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV)
- Conditions
- Hepatitis B
- Interventions
- First Posted Date
- 2017-12-08
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 114
- Registration Number
- NCT03365947
- Locations
- 🇳🇿
Auckland Clinical Studies Limited, Grafton, Auckland, New Zealand
🇳🇿Middlemore Clinical Trials, Papatoetoe, Auckland, New Zealand
🇦🇺Linear Research, Nedlands, Western Australia, Australia
Study of ARO-AAT in Normal Adult Volunteers
- Conditions
- Alpha 1-Antitrypsin Deficiency
- Interventions
- Other: Sterile Normal Saline (0.9% NaCl)
- First Posted Date
- 2017-12-05
- Last Posted Date
- 2020-08-18
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 45
- Registration Number
- NCT03362242
- Locations
- 🇳🇿
Auckland Clinical Studies Limited, Grafton, Auckland, New Zealand
Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels
- Conditions
- Alpha-1 Antitrypsin Deficiency
- Interventions
- Drug: ARC-AAT Injection
- First Posted Date
- 2016-09-14
- Last Posted Date
- 2017-05-18
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Registration Number
- NCT02900183
- Locations
- 🇮🇪
Beaumont Hospital, Dublin, Ireland
🇨🇦Inspiration Research Limited, Toronto, Ontario, Canada
🇮🇹IRCCS Policlinico San Matteo Foundation, University of Pavia, Pavia, Italy
A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB)
- Conditions
- Hepatitis B
- Interventions
- Drug: ARC-521 InjectionOther: PlaceboDrug: antihistamine
- First Posted Date
- 2016-06-13
- Last Posted Date
- 2018-09-25
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 47
- Registration Number
- NCT02797522
- Locations
- 🇳🇿
Auckland Clinical Studies Ltd, Grafton, Auckland, New Zealand
Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection
- Conditions
- Hepatitis B
- Interventions
- First Posted Date
- 2016-04-14
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 12
- Registration Number
- NCT02738008
- Locations
- 🇰🇷
Gachon University Gil Medical Center, Incheon, Korea, Republic of
🇨🇳Queen Mary Hospital, Hong Kong, China
🇩🇪Eugastro Gmbh, Leipzig, Germany
A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection
- Conditions
- Hepatitis B
- Interventions
- First Posted Date
- 2015-11-13
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 58
- Registration Number
- NCT02604199
- Locations
- 🇰🇷
Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of
🇩🇪Eugastro Gmbh, Leipzig, Germany
🇩🇪University Hospital of Tuebingen, Tuebingen, Germany
A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection
- Conditions
- Hepatitis B
- Interventions
- First Posted Date
- 2015-11-13
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 32
- Registration Number
- NCT02604212
- Locations
- 🇩🇪
Universitaetsklinikum Leipzig, Leipzig, Germany
🇩🇪Universitaetsklinikum Wuerzburg, Medizinische Klinik Und Poliklinik II, Wuerzburg, Germany
🇩🇪Medizinische Hochschule Hannover, Hannover, Germany
Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)
- Conditions
- Hepatitis DHepatitis B
- Interventions
- Drug: antihistamineBiological: pegylated interferon alpha 2a
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2019-04-12
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 79
- Registration Number
- NCT02577029
- Locations
- 🇦🇺
St. Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia
🇦🇺Westmead Hospital, Westmead, New South Wales, Australia
🇦🇺Concord Repatriation General Hospital, Gastroenterology & Liver Services, Concord, New South Wales, Australia
A Study of ARC-520 at Varying Infusion Rates in Healthy Adult Volunteers
- First Posted Date
- 2015-08-28
- Last Posted Date
- 2018-02-26
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT02535416
- Locations
- 🇦🇺
QPharm, Pty Limited, Royal Brisbane Hospital, Herston, Queensland, Australia